ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
30 announcements with these filters
Promoters sold a total of 15.12 lakh shares via open market transactions, aggregating to ₹106.43 Crore.
Aarti Pharmalabs reported directorate changes, including Shri Rashesh Gogri's appointment as Managing Director, Smt. Hetal Gogri Gala's re-designation, and the cessation of Shri Rajendra Gogri.
Aarti Pharmalabs promoters sold a net 29.03 lakh shares, reducing their stake from 42.88% to 39.66%. No transaction value is disclosed in this periodic SAST filing.
7th AGM presentation for Aarti Pharmalabs. Reported Standalone FY26 Revenue of INR 1,798 Cr with 23% EBITDA margin; Consolidated revenue down 14% YoY to INR 1,819 Cr.
Aarti Pharmalabs conducted its 7th Annual General Meeting on September 22, 2026, to transact ordinary and special business, with voting results to follow.
Promoter Group entities, Safechem Enterprises and Relacion Trusteeship, sold 1,19,400 shares of Aarti Pharmalabs in the open market for a total of ₹10.43 Crore.
Safechem Enterprises Private Limited, part of the promoter group, sold 30,000 equity shares of Aarti Pharmalabs Ltd in the open market.
Aarti Pharmalabs received an order from the Superintendent of Stamps, Gujarat, demanding ₹59.50 Crore for stamp duty and penalties related to a past demerger scheme.
Promoter group entity Safechem Enterprises Private Limited sold 600 equity shares of Aarti Pharmalabs Ltd on the market.
Shri G.M. Naidu, Manufacturing/Sr. General Manager, has resigned from Aarti Pharmalabs Limited. He will be relieved from his duties effective August 31, 2026.
Aarti Pharmalabs Ltd has issued a notice for its 7th Annual General Meeting scheduled for September 22, 2026, via video conferencing to transact six agenda items.
Aarti Pharmalabs has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 as per SEBI regulations.
Aarti Pharmalabs Ltd has filed its Annual Report for the financial year 2025-26, along with the notice for its 7th Annual General Meeting.
Aarti Pharmalabs Ltd has fixed September 15, 2026, as the record date for the payment of a final dividend of ₹2.00 per share for FY 2025-26.
APL reported robust Q1FY27 consolidated revenue of INR 5,358 Mn (+38.7% YoY) with EBITDA margins improving to 24.75%. Management is focusing on high-margin CDMO and Xanthine capacity expansion.
Aarti Pharmalabs Ltd reported changes in designation for directors Mr. Rashesh C. Gogri and Ms. Hetal Gogri Gala, effective October 1, 2026.
Aarti Pharmalabs Ltd announced a change in designation for directors Rashesh C. Gogri and Hetal Gogri Gala, effective October 1, 2026.
Aarti Pharmalabs Ltd reported revenue from operations of ₹535.8 Cr (+38.7% YoY) and net profit of ₹76.1 Cr (+65.4% YoY) for Q1 FY27.
Aarti Pharmalabs scheduled a Board Meeting for August 7, 2026. The board will consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Aarti Pharmalabs inaugurated a new manufacturing block at Tarapur. Total Xanthine derivatives capacity increased to 9600 TPA.
Aarti Pharmalabs allotted 22,062 equity shares under its PSOP 2023 plan. This follows the exercise of stock options by eligible employees.
Aarti Pharmalabs reported Q4 FY26 revenue of ₹580 Cr (+9% YoY) but PAT declined to ₹62 Cr from ₹89 Cr due to higher costs and forex losses.
Aarti Pharmalabs reported FY26 standalone revenue of INR 17,976 Mn with a 23% EBITDA margin. Strategy focuses on CDMO expansion and backward integration for Xanthine derivatives.
Aarti Pharmalabs re-appointed its cost and internal auditors for 12 months. Additionally, Rajendra Pagare and Sachin Patil were designated as Senior Management Personnel.
Aarti Pharmalabs Limited recommended a final dividend of ₹0.4 per equity share for the financial year. The record date will be announced in due course.
Aarti Pharmalabs granted 57,600 stock options to employees at Rs. 5 each. This move under PSOP 2023 aims to align employee interests with shareholders.
Aarti Pharmalabs Ltd reported revenue from operations of ₹582.6 Cr (+3.3% YoY) and net profit of ₹61.1 Cr (-30.8% YoY) for Q4 FY26.
Aarti Pharmalabs reported its FY26 audited financial results and recommended a final dividend of Rs. 2 per share. The board also re-appointed cost and internal auditors.
Aarti Pharmalabs postponed its May 18 board meeting to May 25, 2026. The trading window remains closed until May 27 following financial results declaration.
Aarti Pharmalabs scheduled a May 18, 2026 board meeting to approve FY26 results and final dividend. Investors should track these upcoming financial disclosures.